TG Therapeutics CEO to Present at Cantor Healthcare Conference
Event summary
- TG Therapeutics CEO Michael S. Weiss to participate in Cantor Global Healthcare Conference on September 9, 2026.
- Fireside chat scheduled for 11:30am ET.
- Live webcast available on TG Therapeutics' Investors & Media page.
- TG Therapeutics focuses on B-cell diseases, with FDA-approved BRIUMVI® for relapsing forms of multiple sclerosis.
- Company has international regulatory approvals for BRIUMVI®.
The big picture
TG Therapeutics' participation in the Cantor Global Healthcare Conference comes as the biotech sector continues to focus on innovative treatments for autoimmune diseases. The company's FDA-approved BRIUMVI® positions it as a key player in the relapsing MS market, with potential for further international expansion. Investors will be watching for updates on commercialization efforts and pipeline progress.
What we're watching
- Market Positioning
- How TG Therapeutics will leverage the conference to highlight BRIUMVI®'s market potential in relapsing MS.
- Regulatory Strategy
- Whether the company can expand BRIUMVI®'s approvals beyond the U.S. and into new indications.
- Execution Risk
- The pace at which TG Therapeutics can commercialize its pipeline and maintain growth momentum.
Related topics